Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Ann Rheum Dis. 2016 Nov 9;76(4):740–747. doi: 10.1136/annrheumdis-2016-209850

Figure 4. KD025 and Y27632 regulate distinct subset of immune-relevant genes.

Figure 4

Following preliminary low-stringency NanoString screening for genes differentially expressed in Th17 cells treated with KD025, Y27632 we performed principal component analysis of independent cell samples (the sample coding is shown next to the data points) with gene expression as variables. (A) The first four principal components (PC) explain 77.7% of variance. (B) The first PC separates Y27632/SMV-treated Th17 cells from untreated (NT) and KD025-treated Th17 cells, whereas the second PC separates KD025-treated and NT cells. (C) Unsupervised hierarchical clustering were used to define the group of co-regulated genes I Th17 cells following treatments with Y27632, SMV or KD025 in comparison to not-treated cells. Genes specifically downregulated in KD025-treated cells (Cluster I) are shown in red, cluster IIC that contains a group of genes specifically downregulated by Y27632 is shown in blue, and cluster IIIB combines genes downregulated in Th17 cells treated with either Y27632 or KD025